Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Significance: Psychedelic compounds, such as psilocybin, have beneficial actions in several psychiatric diseases. They also produce strong alterations of consciousness, which may be a barrier to their widespread use. We found that psilocybin has fast-acting antidepressant-like properties in mice. Using multiple assays of hedonic behavior and an antagonist of prohallucinatory 5-HT2A receptors, we further suggest that altered perception may not be necessary for its therapeutic actions. We also showed that psilocybin strengthens connections between brain cells in regions important for processing rewards and emotions. These experiments suggest that it may be possible to retain the beneficial actions of psilocybin while minimizing the alterations in consciousness, thereby accelerating its use in the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Thus, to block the 5-HT 2A R can not produce the antidepressant effects of psilocybin, only induce the hallucinogenic-like behaviors in mice. 386”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [386]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Psilocybin increases the head size of spines on cortical neurons (Shao et al., 2021) and the AMPA/NMDA ratio at synapses of the hippocampal CA1 pyramidal neurons (Hesselgrave et al., 2021), both suggesting an increase in synaptic strength.”
From Psychedelics and Neural Plasticity: Therapeutic Implications (2022) · cites this paper as Hesselgrave et al., 2021
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This proposes 5-HT 2A R may not be the real pharmacological target for its antidepressant effects.”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [386]
The cited source says what the claim attributes to it.
In the citing paper
“Taking hippocampal brain slices from these same mice revealed that psilocybin also restored the strength of the stress-sensitive TA-CA1 synapses, concurrent with the restoration of reward behavior, again much like other fastacting antidepressants.”
From Plasticity of synapses and reward circuit function in the genesis and treatment of depression (2023) · cites this paper as [275]
The cited source says what the claim attributes to it.
In the citing paper
“Psilocybin increases the head size of spines on cortical neurons (Shao et al., 2021) and the AMPA/NMDA ratio at synapses of the hippocampal CA1 pyramidal neurons (Hesselgrave et al., 2021), both suggesting an increase in synaptic strength.”
From Psychedelics and Neural Plasticity: Therapeutic Implications (2022) · cites this paper as Hesselgrave et al., 2021
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207 · cited 1×
“There is anatomical evidence that psilocybin may promote synaptic connectivity in the prefrontal cortex in stress-naive mice via a 5-HT2R–dependent mechanism (31).”
BackgroundDuman, R. S., Sanacora, G., & Krystal, J. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.03.013 · Cited by 1,026
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018 · cited 2×
“Blocking 5-HT2A/2CRs with ketanserin eliminates self-reported psychedelic perceptual distortions (8).”
MethodPsilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970
The chronic mild stress (CMS) model of depression: History, evaluation and usage
Willner, P. (2017) · Neurobiology of Stress · doi:10.1016/j.ynstr.2016.08.002 · Cited by 959
González-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925 · cited 1×
“1 twitch/3 to 4 min to 1 twitch/min) (19).”
Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00974 · Cited by 808
Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation
Moda-Sava, R. N., Murdock, M. H., Parekh, P. K., Fetcho, R. N., Huang, B. S., Huynh, T. N., Witztum, J., Shaver, D. C., Rosenthal, D. L., Alway, E. J., et al. (2019) · Science · doi:10.1126/science.aat8078 · Cited by 643
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms
Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, J. N., Wall, M. B., Tanner, M., Kaelen, M., McGonigle, J., Murphy, K., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13282-7 · Cited by 587
The subjective effects of psychedelics are necessary for their enduring therapeutic effects
Yaden, D. B., & Griffiths, R. R. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00194 · Cited by 541 · cited 2×
“There is a widespread expectation that these psilocybininduced alterations in consciousness are essential to the antidepressant response (2, 9, 10); however, this hypothesis has never been tested clinically or preclinically.”
BackgroundMadsen, M. K., Fisher, P. M., Burmester, D., Dyssegaard, A., Stenbæk, D. S., Kristiansen, S., Johansen, S. S., Lehel, S., Linnet, K., Svarer, C., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0324-9 · Cited by 517 · cited 1×
“In humans, the intensity of psilocybininduced perceptual changes is correlated with serotonin 2A receptor (5-HT2AR) activation (7).”
BackgroundA non-hallucinogenic psychedelic analogue with therapeutic potential
Cameron, L. P., Tombari, R. J., Lu, J., Pell, A. J., Hurley, Z. Q., Ehinger, Y., Vargas, M. V., McCarroll, M. N., Taylor, J. C., Myers-Turnbull, D., et al. (2021) · Nature · doi:10.1038/s41586-020-3008-z · Cited by 473 · cited 3×
“Although the actions of psychedelics have been well characterized in a number of mouse behaviors, including head twitches (12) and escape behaviors (13, 14), the efficacy of psychedelics has not been sufficiently studied in well-validated animal models of”
BackgroundMultiple receptors contribute to the behavioral effects of indoleamine hallucinogens
Halberstadt, A. L., & Geyer, M. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.017 · Cited by 411 · cited 4×
“Mice were injected with a high dose of psilocybin (5 mg/kg) known to induce hypolocomotion (6) 60 min after pretreatment.”
BackgroundMethodInfluentialEmotions and brain function are altered up to one month after a single high dose of psilocybin.
Barrett, F. S., Doss, M. K., Sepeda, N. D., Pekar, J. J., & Griffiths, R. R. (2020) · Scientific Reports · doi:10.1038/s41598-020-59282-y · Cited by 375 · cited 3×
“These results demonstrate that a single psilocybin administration in rodents promotes persistent synaptic strengthening in a depression-relevant brain region days after its elimination from the body (hours), much like the persistent effects of psilocybin on human brain functional connectivity (32).”
BackgroundResultKometer, M., Schmidt, A., Jancke, L., & Vollenweider, F. X. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.3007-12.2013 · Cited by 355 · cited 1×
“In humans, psilocybin decreases low-frequency electroencephalographic oscillations in cortical and limbic areas via activation of ketanserin-sensitive 5-HT2ARs (21).”
BackgroundJohnson, M. W., Griffiths, R. R., Hendricks, P. S., & Henningfield, J. E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.012 · Cited by 354
Psychedelic Psychiatry’s Brave New World
Nutt, D., Erritzoe, D., & Carhart-Harris, R. (2020) · Cell · doi:10.1016/j.cell.2020.03.020 · Cited by 319
Kometer, M., Schmidt, A., Bachmann, R., Studerus, E., Seifritz, E., & Vollenweider, F. X. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.04.005 · Cited by 298 · cited 3×
“Indeed, human studies with healthy volunteers and TRD patients reveal persistent increases in functional connectivity in these same circuits after psilocybin administration (11, 32, 35).”
BackgroundHalberstadt, A. L., Chatha, M., Klein, A. K., Wallach, J., & Brandt, S. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107933 · Cited by 278
An excitatory synapse hypothesis of depression
Thompson, S. M., Kallarackal, A. J., Kvarta, M. D., Van Dyke, A. M., LeGates, T. A., & Cai, X. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2015.03.003 · Cited by 265 · cited 1×
“Importantly, responses to rewarding stimuli in stressed animals are restored by compounds that have antidepressant efficacy in humans, including fast- and slow-acting compounds such as ketamine and selective serotonin reuptake inhibitors (SSRIs), when administered acutely and chronically, respectively (16).”
BackgroundSelf-citationHalberstadt, A. L., Koedood, L., Powell, S. B., & Geyer, M. A. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110388326 · Cited by 213 · cited 4×
“Vehicle-pretreated mice receiving psilocybin demonstrated significantly more head twitching compared to mice receiving vehicle or ketanserin alone, serving as a behavioral indication of 5-HT2AR activation by psychedelic compounds (17).”
BackgroundMethodInfluentialHibicke, M., Landry, A. N., Kramer, H. M., Talman, Z. K., & Nichols, C. D. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00493 · Cited by 205 · cited 4×
“Although psilocybin has been reported to have delayed antidepressant-like effects in the forced swim test in some, but not all, strains of rats (13, 33), we were unable to replicate this finding in mice.”
BackgroundMethodInfluentialKallarackal, A. J., Kvarta, M. D., Cammarata, E., Jaberi, L., Cai, X., Bailey, A. M., & Thompson, S. M. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2588-13.2013 · Cited by 181 · cited 2×
“3D) in mice treated with psilocybin, consistent with the effects of chronically administered fluoxetine described previously (24).”
BackgroundMethodSelf-citationCai, X., Kallarackal, A. J., Kvarta, M. D., Goluskin, S., Gaylor, K., Bailey, A. M., Lee, H.-K., Huganir, R. L., & Thompson, S. M. (2013) · Nature Neuroscience · doi:10.1038/nn.3355 · Cited by 180 · cited 2×
“Our previous work has suggested that 5-HT1BRs contribute to the synaptic and behavioral antidepressantlike actions of SSRIs (36).”
BackgroundSelf-citationEvans, J. W., Szczepanik, J., Brutsché, N., Park, L. T., Nugent, A. C., & Zarate, C. A. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.01.027 · Cited by 173 · cited 1×
“In contrast, antidepressants promote restoration of excitatory synaptic transmission in reward circuits after chronic stress (16, 23–25) and restoration of functional connectivity in humans (26).”
BackgroundCelada, P., Puig, M. V., Díaz-Mataix, L., & Artigas, F. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.03.013 · Cited by 143
Investigation of the Structure–Activity Relationships of Psilocybin Analogues
Klein, A. K., Chatha, M., Laskowski, L. J., Anderson, E. I., Brandt, S. D., Chapman, S. J., McCorvy, J. D., & Halberstadt, A. L. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00176 · Cited by 109 · cited 1×
“Psilocybin injections were given at 1 mg/kg and ketanserin at 2 mg/kg, consistent with previous rodent studies (13, 38), or equivalent volumes of saline.”
MethodLi, Q., Nakadate, K., Tanaka‐Nakadate, S., Nakatsuka, D., Cui, Y., & Watanabe, Y. (2004) · Journal of Comparative Neurology · doi:10.1002/cne.11004 · Cited by 99
Psilocybin-induced stimulus control in the rat
Winter, J. C., Rice, K. C., Amorosi, D. J., & Rabin, R. A. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.06.003 · Cited by 86 · cited 2×
“), as shown to be effective in previous rat behavioral studies (18), followed 1 h later by psilocybin (1 mg/kg, i.”
BackgroundMethodLambe, E. K., & Aghajanian, G. K. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300944 · Cited by 75 · cited 1×
“Psychedelic compounds exert acute electrophysiological effects via 5-HT2AR activation in the cortex and hippocampus (29, 30).”
BackgroundDossat, A. M., Wright, K. N., Strong, C. E., & Kabbaj, M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.022 · Cited by 72
Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat
Jefsen, O., Højgaard, K., Christiansen, S. L., Elfving, B., Nutt, D. J., Wegener, G., & Müller, H. K. (2019) · Acta Neuropsychiatrica · doi:10.1017/neu.2019.15 · Cited by 63 · cited 2×
“Although psilocybin has been reported to have delayed antidepressant-like effects in the forced swim test in some, but not all, strains of rats (13, 33), we were unable to replicate this finding in mice.”
BackgroundWyskiel, D. R., & Andrade, R. (2016) · Hippocampus · doi:10.1002/hipo.22611 · Cited by 32 · cited 1×
“Psychedelic compounds exert acute electrophysiological effects via 5-HT2AR activation in the cortex and hippocampus (29, 30).”
BackgroundGalvanho, J. P., Manhães, A. C., Carvalho-Nogueira, A. C. C., Silva, J. D. M., Filgueiras, C. C., & Abreu‐Villaça, Y. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109775 · Cited by 17 · cited 1×
“As in previously published reports (6, 20), pretreatment with ketanserin induced hypolocomotion, directly and/or by enhancing the effects of psilocybin (SI Appendix, Fig.”
Cited by
Major depressive disorder: hypothesis, mechanism, prevention and treatment
Cui, L., Li, S., Wang, S., Wu, X., Liu, Y., Yu, W., Wang, Y., Tang, Y., Xia, M., & Li, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01738-y · Cited by 1,244
“386 This proposes 5-HT 2A R may not be the real pharmacological target for its antidepressant effects.”
BackgroundBogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., Mennenga, S. E., O’Donnell, K., Owens, L. T., Podrebarac, S., et al. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.2096 · Cited by 711
Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021) · Neuron · doi:10.1016/j.neuron.2021.06.008 · Cited by 626
Psychedelics promote plasticity by directly binding to BDNF receptor TrkB
Moliner, R., Girych, M., Brunello, C. A., Kovaleva, V., Biojone, C., Enkavi, G., Antenucci, L., Kot, E. F., Goncharuk, S. A., Kaurinkoski, K., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01316-5 · Cited by 478
Psychedelics reopen the social reward learning critical period
Nardou, R., Sawyer, E., Song, Y. J., Wilkinson, M., Padovan-Hernandez, Y., de Deus, J. L., Wright, N., Lama, C., Faltin, S., Goff, L. A., et al. (2023) · Nature · doi:10.1038/s41586-023-06204-3 · Cited by 358
Metadata
- Authors
- Hesselgrave, N., Troppoli, T. A., Wulff, A. B., Cole, A. B., & Thompson, S. M.
- Affiliations
- University of Maryland, Baltimore (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2021-04-13
- Volume
- 118
- Issue
- 17
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC8092378
- OpenAlex
- W3155245221
- Cited by
- 378
- References
- 37
- Citations by year
- 2026: 59 · 2025: 92 · 2024: 74 · 2023: 81 · 2022: 49 · 2021: 22
- FWCI
- 38.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Office of Extramural Research, National Institutes of Health (R01 MH086828, T32 GM008181, T32 GM136561)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- psilocybin, antidepressant effects, depression, 5-HT2A receptor, ketanserin, anhedonia, chronic stress, hippocampal synaptic plasticity, excitatory synapses, altered states of consciousness, reward systems, psychedelic therapy
- MeSH terms
- Animals, Depression, Drug Evaluation, Preclinical, Hallucinogens, Hippocampus, Ketanserin, Male, Mice, Inbred C57BL, Psilocybin, Stress, Psychological, Receptors, Serotonin, 5-HT2, Mice, Serotonin 5-HT2 Receptor Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.